CD8A and neoplasm: First, in a prophylactic setting, TA presentation by engineered liver macrophages primes naïve CD8+ T cells, whereas in a therapeutic setting, liver macrophages present the antigen to T cells, which were already primed in the tumor or in tumor-draining lymph nodes.